A Study to Better Understand How to Predict and Manage Patients Who are at High Risk for Developing Rheumatic Immune-related Adverse Events While Receiving Treatment for Melanoma

Overview

About this study

The purpose of this study is to:

  1. Understanding how to better predict and manage patients at high risk for rheumatic irAEs and tailor therapy without diminishing cancer treatment efficacy and,
  2. Further inform our understanding on the pathogenesis of classic rheumatologic diseases.
  3. Establish a repository of biological samples from patients with irAE and corresponding rheumatologic

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

From the Melanoma Clinic at Mayo Clinic, the aim is to recruit the following groups of melanoma patients receiving ICI therapy:

  • Patients without pre-existing rheumatologic disease, who have not developed any irAE at recruitment.
  • Patients with pre-existing rheumatologic disease, who have not developed any irAE at recruitment.
  • Patients without pre-existing rheumatologic disease who have developed any non-rheumatic irAE.
  • Patients without pre-existing rheumatologic disease who develop a de novo rheumatic irAE.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Uma Thanarajasingam, M.D., Ph.D.

Closed for enrollment

Contact information:

Jane Jaquith C.C.R.C.

(507) 284-4502

jaquith.jane@mayo.edu

More information

Publications

Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions